Larry Hsu had already completed the arc that business profiles are built to celebrate. He had spent 15 years learning pharmaceutical development inside Abbott, co-founded Impax in 1995, guided it into the public markets, and watched it grow beyond 1,000 employees. When he retired in April 2014, the company’s market value was reported near $3 billion. The ending was tidy. Hsu chose not to keep it.
He started LifeMax Laboratories to work on new drug development. He helped launch venture funds for other young companies. Six years after leaving Impax, he founded AmMax Bio through a partnership with Amgen. He was back in the least glamorous phase of the company cycle: licensed rights, compact teams, technical risk, and years measured in development milestones rather than quarters.
The return makes more sense when Hsu’s career is read from the laboratory outward. His doctorate, earned at the University of Michigan in 1981, is in pharmaceutics. His undergraduate degree from National Taiwan University is in pharmacy. At Abbott, where he became director of product development, his remit reached across formulation, process engineering, clinical-supply manufacturing, and production support. These are disciplines of conversion. A molecule is only the opening argument; the job is to make it reproducible, testable, manufacturable, and eventually useful.
The company inside the compound
Impax began as a drug-delivery and formulation company. Its early identity was not a consumer brand or a single heroic discovery. It was a set of capabilities for developing controlled-release and other specialized dosage forms. Hsu appears on patents involving combinations of immediate-release and controlled-release components. The work was technical, but its commercial logic was plain: take the difficult middle of pharmaceutical development seriously, and it can become a company.
In 1999, Impax entered public markets through a reverse acquisition of Global Pharmaceuticals and took the Impax Laboratories name. It was an unceremonious route compared with a ringing bell and a fresh IPO prospectus, but it provided a structure for the next phase. Hsu remained president and added the CEO role in 2006. During his tenure, Impax formed partnerships with Teva, AstraZeneca, Pfizer, and Shire. The company divided its attention between generic pharmaceuticals and differentiated branded programs, applying formulation expertise as both product craft and business strategy.
The interesting asset was never only a compound. It was the organization capable of carrying that compound through the next gate.A pattern across Abbott, Impax, LifeMax, and AmMax
By 2013, Impax reported roughly $511 million in annual revenue. Scale brought factories, filings, partnerships, and the administrative weight of a listed manufacturer. It also turned the founder’s original technical instincts into systems. Hsu’s company biography says Impax was close to a $3 billion market value when he retired. The University of Michigan’s College of Pharmacy used the same broad record when it gave him its Alumni Distinguished Lifetime Achievement Award in 2015.
There was another role inside that growth: allocator. A development company has to choose where its scarce attention goes long before the market supplies a verdict. Impax had formulation platforms, generic opportunities, and branded ambitions competing for the same institutional bandwidth. Hsu’s later work as a general partner in two venture funds extended that judgment beyond one corporate pipeline. The object changed from choosing projects inside a company to helping choose companies themselves, but the underlying question remained familiar: which combination of evidence, people, and timing deserves another round of resources?
The timing of that award carries a small joke. Hsu had reached “lifetime achievement” just as he was returning to startup work.
Earns a PhD in pharmaceutics from the University of Michigan.
Co-founds the company that becomes Impax Laboratories.
Impax becomes public through a reverse acquisition.
Retires from Impax and starts LifeMax Laboratories.
Founds AmMax Bio in partnership with Amgen.
Adds Lonza ADC technology and a president and COO.
Beginning again, with memory
A second-time founder does not actually begin at zero. The cap table may be new. The systems, people, and hypotheses are new. But memory arrives fully vested. Hsu knew the cost of moving a program from development into manufacturing. He knew partnerships could create leverage long before headcount could. He also knew that a pharmaceutical company can spend years being evaluated by milestones that are meaningful to specialists and nearly invisible to everyone else.
AmMax began in 2020 when LifeMax and Amgen formed the company around exclusive worldwide rights to a clinical-stage monoclonal antibody. That origin set a pattern. Rather than presenting every scientific component as an invention born inside its own walls, AmMax would assemble programs through licensing, translational work, and collaboration. The company remained small enough for each external relationship to alter its shape.
The name itself quietly connects the two sides of the deal: Amgen and LifeMax. More important is what each side contributed. Amgen brought a studied antibody asset. LifeMax brought a development organization led by someone who had taken products through the less visible disciplines of pharmaceutical work. The new company became the vessel in between. It could focus capital and management around a program without recreating the larger institutions that had produced its parts.
The portfolio has changed as evidence and strategy developed. In late 2024, AmMax and MD Anderson announced agreements around AMB-066, including a Phase 2a study. In January 2025, the company announced that the first patient had been dosed. By 2026, AmMax was putting more emphasis on antibody-drug conjugates, which pair a targeting antibody with a cytotoxic payload. The company’s lead ADC program, AMB-104, was being prepared for an expected early-2027 regulatory submission and clinical start.
The strategy is visible in the component choices. AmMax describes its approach as using clinically validated elements where possible: a targeting antibody with an existing body of data, a linker-payload platform developed elsewhere, and outside manufacturing expertise. None of this removes development risk. It changes the portfolio of risks the company is volunteering to carry.
Hiring for the next gate
In June 2026, AmMax announced two moves one week apart. First came a non-exclusive license to use Lonza’s GlycoConnect, HydraSpace, and SYNtecan technologies in AMB-104. Then Travis Read joined as president and chief operating officer, with responsibility for operating strategy, business development, and financing.
The pairing is revealing. A new technical relationship created a different set of organizational needs. Read’s experience spans capital deployment, company creation, and preclinical operations. Hsu described the appointment in practical verbs: entering the clinic, advancing the pipeline, supporting the team. The founder remained CEO, while an operator was added to prepare the company for a stage where scientific plans, money, manufacturing, and calendars have to meet.
“We look forward to advancing AMB-104 through clinical trials.”Larry Hsu, on AmMax’s 2026 Lonza agreement
There is restraint in the structure. Hsu has already run the version of a company where more than 1,000 people depend on its systems. AmMax’s public footprint is much smaller. Its leverage comes from the quality of the agreements around it and from a leadership roster assembled for defined problems: antibody science, clinical development, product development, finance, licensing, and now operational scale.
That is the most transferable part of Hsu’s story. Experience is often described as a collection of answers. In company building, it may be more useful as a feel for sequence. Which risk must be resolved first? Which capability belongs inside? When does a scientific partnership require a financing operator? When is a candidate ready to become a program, and when does a program demand a different company?
Sequence also explains why Hsu’s network keeps reappearing in the work. Large pharmaceutical partners mattered at Impax. At AmMax, the board and scientific advisers include veterans of antibody development, oncology research, public-company finance, and earlier Impax chapters. These are not ornamental affiliations. A tiny company cannot employ every kind of experience every day, so it needs people close enough to call before a decision hardens into cost. The network becomes a variable part of the operating system.
The long middle
Hsu’s public comments stay close to milestones. He speaks about agreements, trials, candidates, and the next stage of development. There is little mythology in that vocabulary. The company does not become real at founding, and the science does not become inevitable at licensing. Reality accumulates through handoffs: a development package accepted, a manufacturing process transferred, a study opened, a new specialist hired.
This is where his first career and second act meet. Abbott taught the machinery of development at global scale. Impax turned that machinery into an independent company and carried it into the public markets. LifeMax returned him to research and early assets. AmMax is now testing whether decades of institutional memory can be concentrated inside a small team without burdening it with the architecture of the last company.
The answer will not arrive as a tidy founder parable. It will arrive program by program. AmMax’s current timetable points to early 2027 for AMB-104 to enter clinical development. Before then lie the ordinary, consequential tasks that Hsu has been close to for more than four decades. The second act looks less like reinvention than a return to the work beneath the title: deciding what must become true next, then building the organization that can make it happen.